Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19

Jing Chun Song; Gang Wang; Wei Zhang; Yang Zhang; Wei Qin Li; Zhou Zhou

doi:10.1186/s40779-020-00247-7

Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19

Jing Chun Song
, Gang Wang
, Wei Zhang
, Yang Zhang
, Wei Qin Li
, Zhou Zhou

908th Hospital of Joint Logistics Support Forces of Chinese PLA
The Second Affiliated Hospital of Xi'an Jiaotong University
900th Hospital of Joint Logistics Support Forces of Chinese PLA
Chinese Academy of Medical Sciences
Nanjing General Hospital

Research output: Contribution to journal › Article › peer-review

126 Scopus citations

Abstract

Since December 2019, a novel type of coronavirus disease (COVID-19) in Wuhan led to an outbreak throughout China and the rest of the world. To date, there have been more than 1,260,000 COVID-19 patients, with a mortality rate of approximately 5.44%. Studies have shown that coagulation dysfunction is a major cause of death in patients with severe COVID-19. Therefore, the People’s Liberation Army Professional Committee of Critical Care Medicine and Chinese Society on Thrombosis and Hemostasis grouped experts from the frontline of the Wuhan epidemic to come together and develop an expert consensus on diagnosis and treatment of coagulation dysfunction associated with a severe COVID-19 infection. This consensus includes an overview of COVID-19-related coagulation dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy, supportive therapy and prevention. The consensus produced 18 recommendations which are being used to guide clinical work.

Original language	English
Article number	02000247
Journal	Military Medical Research
Volume	7
Issue number	1
DOIs	https://doi.org/10.1186/s40779-020-00247-7
State	Published - 2020
Externally published	Yes

Keywords

COVID-19
Coagulation dysfunction
Diagnosis
Severe
Treatment

Access to Document

10.1186/s40779-020-00247-7

Cite this

@article{b8fbc1e35022465fa883804e6179a999,

title = "Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19",

abstract = "Since December 2019, a novel type of coronavirus disease (COVID-19) in Wuhan led to an outbreak throughout China and the rest of the world. To date, there have been more than 1,260,000 COVID-19 patients, with a mortality rate of approximately 5.44\%. Studies have shown that coagulation dysfunction is a major cause of death in patients with severe COVID-19. Therefore, the People{\textquoteright}s Liberation Army Professional Committee of Critical Care Medicine and Chinese Society on Thrombosis and Hemostasis grouped experts from the frontline of the Wuhan epidemic to come together and develop an expert consensus on diagnosis and treatment of coagulation dysfunction associated with a severe COVID-19 infection. This consensus includes an overview of COVID-19-related coagulation dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy, supportive therapy and prevention. The consensus produced 18 recommendations which are being used to guide clinical work.",

keywords = "COVID-19, Coagulation dysfunction, Diagnosis, Severe, Treatment",

author = "Song, \{Jing Chun\} and Gang Wang and Wei Zhang and Yang Zhang and Li, \{Wei Qin\} and Zhou Zhou",

note = "Publisher Copyright: {\textcopyright} The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.",

year = "2020",

doi = "10.1186/s40779-020-00247-7",

language = "英语",

volume = "7",

journal = "Military Medical Research",

issn = "2095-7467",

publisher = "KeAi Communications Co.",

number = "1",

}

TY - JOUR

T1 - Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19

AU - Song, Jing Chun

AU - Wang, Gang

AU - Zhang, Wei

AU - Zhang, Yang

AU - Li, Wei Qin

AU - Zhou, Zhou

N1 - Publisher Copyright: © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

PY - 2020

Y1 - 2020

N2 - Since December 2019, a novel type of coronavirus disease (COVID-19) in Wuhan led to an outbreak throughout China and the rest of the world. To date, there have been more than 1,260,000 COVID-19 patients, with a mortality rate of approximately 5.44%. Studies have shown that coagulation dysfunction is a major cause of death in patients with severe COVID-19. Therefore, the People’s Liberation Army Professional Committee of Critical Care Medicine and Chinese Society on Thrombosis and Hemostasis grouped experts from the frontline of the Wuhan epidemic to come together and develop an expert consensus on diagnosis and treatment of coagulation dysfunction associated with a severe COVID-19 infection. This consensus includes an overview of COVID-19-related coagulation dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy, supportive therapy and prevention. The consensus produced 18 recommendations which are being used to guide clinical work.

AB - Since December 2019, a novel type of coronavirus disease (COVID-19) in Wuhan led to an outbreak throughout China and the rest of the world. To date, there have been more than 1,260,000 COVID-19 patients, with a mortality rate of approximately 5.44%. Studies have shown that coagulation dysfunction is a major cause of death in patients with severe COVID-19. Therefore, the People’s Liberation Army Professional Committee of Critical Care Medicine and Chinese Society on Thrombosis and Hemostasis grouped experts from the frontline of the Wuhan epidemic to come together and develop an expert consensus on diagnosis and treatment of coagulation dysfunction associated with a severe COVID-19 infection. This consensus includes an overview of COVID-19-related coagulation dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy, supportive therapy and prevention. The consensus produced 18 recommendations which are being used to guide clinical work.

KW - COVID-19

KW - Coagulation dysfunction

KW - Diagnosis

KW - Severe

KW - Treatment

UR - https://www.scopus.com/pages/publications/85083755600

U2 - 10.1186/s40779-020-00247-7

DO - 10.1186/s40779-020-00247-7

M3 - 文章

C2 - 32307014

AN - SCOPUS:85083755600

SN - 2095-7467

VL - 7

JO - Military Medical Research

JF - Military Medical Research

IS - 1

M1 - 02000247

ER -

Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this